The fourth Journal Club

The following manuscript will be discussed:
The SGLT2 inhibitor empagliflozin promotes increased fatty acid oxidation in skeletal muscle cells.

It is a recent publication that investigates the mechanisms of action of empagliflozin, a medication used in clinics with beneficial effects on the heart. Authors examined effects of empagliflozin on the metabolism of glucose and fatty acids in models of skeletal muscle cells.

Organized by the VRC Cardiovascular Research.